This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognizing you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful
Activities:
REDEFAR kick-off event held in Santiago de Compostela on 27 and 28 February 2018.
-
REDEFAR meeting held in Santiago de Compostela on 19 May 2016. A study of the research funding opportunities at regional (Autonomous community) level via European structural funds 2014-2020.
-
Collaboration in organizing, along with BIB, the “International Symposium on Rare Diseases and Big Data: from research to clinical practice”, Fundación Ramón Areces, held on 26 – 27 October 2017 in Barcelona.
-
Participation in the VII Congress of Spanish Drug Discovery Network (SDDN) held in Santiago de Compostela on 2-4 November 2017.
-
Participation in the X Spanish Technology Platform for Innovative Medicines (PTEMI): 7 and 8 March 2017 in Madrid.
-
Diffusion of the strategic plan of the XI Spanish Technology Platform for Innovative Medicines (PTEMI): 6 March 2018 in Barcelona.
Collaborations and networking:
-
Integration and connection with the ASEBIO working group on drug discovery and rare diseases.
-
Networking actions with pharmaceutical companies in collaboration with PTEMI, for a strategic plan including the public and private sectors.
-
Organization of a meeting/workshop held on 8 March 2017 in Madrid (CIB-CSIC node) to create a strategic plan for early drug discovery in Spain. Public, private and governmental bodies involved in the field of drug discovery in Spain participated in the workshop.
-
REDEFAR and the European Lead Factory (ELF) have signed a Memorandum of Understanding (MoU) in which they declared that both initiatives have a common interest in the discovery and development of small molecules that modulate the biological function of target proteins, recognising that the activities of both initiatives are complementary and are aimed towards the practical application of pharmacological research. The synergy established between both groups and the complementary activities are of great interest.